Drug development, clinical trials, and industry dynamics—what changes timelines, risk, and competitive positioning.
Ascendis Pharma has achieved a milestone with FDA approval of its weekly achondroplasia drug Yuviwel, marking a significant moment in treatments for this rare genetic disorder.
Ascendis Pharma has achieved a milestone with FDA approval of its weekly achondroplasia drug Yuviwel, marking a significant moment in treatments for this rare genetic disorder.
READ MORE
February 2026 witnessed significant executive activity across the healthcare sector, featuring new hires, promotions, and layoffs at prominent organizations such as CDC, Nabla, symplr, Walgreens, Cigna, and Merck.
Boehringer Ingelheim recently acquired rights to oral small molecules from Sitryx, aiming to develop new treatments for autoimmune and inflammatory diseases with potential broad applications.
Contract work opportunities in the biopharma sector have expanded year over year, reflecting a growing preference among employers and professionals for flexible employment arrangements.
LB Pharma navigated a challenging capital market environment in 2025 to secure $350 million for advancing its schizophrenia drug candidate, demonstrating strategic leadership in biotech financing.
Novo Nordisk has implemented significant price cuts for its obesity drugs, but the effect on patients’ costs and accessibility remains complex.
Cancer drug waste costs healthcare billions annually, but enhanced forecasting techniques offer a promising route to reduce inefficiencies.
Gilead Sciences announced a significant acquisition of Arcellx, a company developing a promising CAR-T cell therapy for multiple myeloma, in a $7.8 billion deal.
Bayer has initiated legal proceedings against Johnson & Johnson, accusing the rival company of conducting a false advertising campaign related to prostate cancer treatments.
Novo Nordisk’s next-generation obesity drug CagriSema recently underperformed in a daring head-to-head trial against Eli Lilly’s Zepbound, raising critical questions about its future market positioning.
Two years after their approval, the sickle cell gene therapies Casgevy and Lyfgenia are encountering difficulties gaining market traction, despite ongoing efforts by developers to advance their clinical and commercial prospects.
